{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:26:04Z","timestamp":1790378764057,"version":"4.1.0"},"reference-count":137,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atopic dermatitis (AD) is a common inflammatory skin disease characterized by scaly, oozing skin and itch. In moderate-to-severe AD, treatment options have been historically very limited and off-label use has been a common method for disease management. For decades, ciclosporin A was the only systemic immunosuppressive drug approved in most European countries to address this major unmet medical need. However, increased understanding of the pathophysiology of AD has led to a revolution in the treatment of this potentially debilitating disease. Following the approval of the first biological therapy for AD in 2017, there has been a rapid expansion of compounds under development and four additional systemic therapies have been approved in Europe and the USA within the past 3 years alone. In this review, we underscore how key breakthroughs have transformed the therapeutic landscape of AD, leading to a major expansion of type 2 immunity-targeted biological therapies, exploration of neuroimmune modulatory agents, and interest in Janus kinase inhibition.<\/jats:p>","DOI":"10.1093\/bjd\/ljac016","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T03:56:16Z","timestamp":1673150176000},"page":"698-708","source":"Crossref","is-referenced-by-count":30,"title":["Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies"],"prefix":"10.1093","volume":"188","author":[{"given":"Anna M","family":"Trier","sequence":"first","affiliation":[{"name":"Washington University School of Medicine , St. Louis, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-7161","authenticated-orcid":false,"given":"Brian S","family":"Kim","sequence":"additional","affiliation":[{"name":"Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY , USA"},{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"},{"name":"Friedman Brain Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"},{"name":"Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"2023100619312121000_ljac016-B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023100619312121000_ljac016-B2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"2023100619312121000_ljac016-B3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","article-title":"A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics","volume":"80","author":"Yew","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"2023100619312121000_ljac016-B5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2023100619312121000_ljac016-B7","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3346\/jkms.2010.25.12.1828","article-title":"Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul metropolitan area, Korea","volume":"25","author":"Kim","year":"2010","journal-title":"J\u00a0Korean Med Sci"},{"key":"2023100619312121000_ljac016-B8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"key":"2023100619312121000_ljac016-B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023100619312121000_ljac016-B10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Pediatr Drugs"},{"key":"2023100619312121000_ljac016-B11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","article-title":"Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis","volume":"77","author":"Eichenfield","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40265-022-01722-2","article-title":"New topical therapies in development for atopic dermatitis","volume":"82","author":"Freitas","year":"2022","journal-title":"Drugs"},{"key":"2023100619312121000_ljac016-B16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1684\/ejd.2019.3557","article-title":"More than skin deep: the systemic nature of atopic dermatitis","volume":"29","author":"Oliveira","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2023100619312121000_ljac016-B17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2023100619312121000_ljac016-B18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/all.12498","article-title":"Off-label prescriptions for atopic dermatitis in Europe","volume":"70","author":"Bieber","year":"2015","journal-title":"Allergy"},{"key":"2023100619312121000_ljac016-B19","first-page":"265","article-title":"A new era has begun: treatment of atopic dermatitis with biologics","volume-title":"Allergol Select","author":"St\u00f6lzl","year":"2021"},{"key":"2023100619312121000_ljac016-B20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","article-title":"Eosinophils and atopic dermatitis","volume":"59","author":"Simon","year":"2004","journal-title":"Allergy"},{"key":"2023100619312121000_ljac016-B21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023100619312121000_ljac016-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"2023100619312121000_ljac016-B23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1005","article-title":"Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis","volume":"12","author":"Mack","year":"2020","journal-title":"Sci Transl Med"},{"key":"2023100619312121000_ljac016-B24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ni.2584","article-title":"Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells","volume":"14","author":"Roediger","year":"2013","journal-title":"Nat Immunol"},{"key":"2023100619312121000_ljac016-B25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"key":"2023100619312121000_ljac016-B26","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.1401307","article-title":"Basophils promote innate lymphoid cell responses in inflamed skin","volume":"193","author":"Kim","year":"2014","journal-title":"J Immunol"},{"key":"2023100619312121000_ljac016-B27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","article-title":"A basophil-neuronal axis promotes itch","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"2023100619312121000_ljac016-B28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"2023100619312121000_ljac016-B30","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J\u00a0Med"},{"key":"2023100619312121000_ljac016-B31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"2023100619312121000_ljac016-B32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023100619312121000_ljac016-B34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to &lt;\u00a06 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2023100619312121000_ljac016-B35","author":"Sanofi."},{"key":"2023100619312121000_ljac016-B36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2023100619312121000_ljac016-B37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","article-title":"Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study","volume":"158","author":"Strober","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023100619312121000_ljac016-B38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjd.18958","article-title":"Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany","volume":"183","author":"Abraham","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.002","article-title":"Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID Study A)","volume":"149","author":"Maurer","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B42","author":"Sanofi"},{"key":"2023100619312121000_ljac016-B43","author":"Sanofi"},{"key":"2023100619312121000_ljac016-B44","author":"Sanofi"},{"key":"2023100619312121000_ljac016-B45","author":"PR Newswire"},{"key":"2023100619312121000_ljac016-B46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"2023100619312121000_ljac016-B47","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jdv.13160","article-title":"Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin","volume":"29","author":"Szegedi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619312121000_ljac016-B48","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis \u2013 a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br\u00a0J Dermatol"},{"key":"2023100619312121000_ljac016-B52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B53","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023100619312121000_ljac016-B55","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course \u2013 a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023100619312121000_ljac016-B56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"2023100619312121000_ljac016-B57","first-page":"1061","article-title":"Biological therapies for atopic dermatitis: an update","volume":"17","author":"Deleanu","year":"2019","journal-title":"Exp Ther Med"},{"key":"2023100619312121000_ljac016-B58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023100619312121000_ljac016-B59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2023100619312121000_ljac016-B60","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2018.12.1005","article-title":"The tralokinumab story: nothing is ever simple","volume":"143","author":"Apter","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/ped.2014.0482","article-title":"Relationship between serum interleukin-17F level and severity of atopic dermatitis in children","volume":"28","author":"Park","year":"2015","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"2023100619312121000_ljac016-B62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jdermsci.2012.07.009","article-title":"Possible role of Th17 cells and IL-17 in the pathogenesis of atopic dermatitis in northern China","volume":"68","author":"Ma","year":"2012","journal-title":"J Dermatol Sci"},{"key":"2023100619312121000_ljac016-B63","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T\u00a0cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing Th17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/09546634.2017.1406894","article-title":"A systematic review of ustekinumab in the treatment of atopic dermatitis","volume":"29","author":"Pan","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"2023100619312121000_ljac016-B65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study","volume":"177","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"2023100619312121000_ljac016-B67","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023100619312121000_ljac016-B69","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J Dermatol Sci"},{"key":"2023100619312121000_ljac016-B73","author":"GlobeNewswire"},{"key":"2023100619312121000_ljac016-B74","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"2023100619312121000_ljac016-B75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.02.006","article-title":"Stratum corneum interleukin-33 expressions correlate with the degree of lichenification and pruritus in atopic dermatitis lesions","volume":"201","author":"Nakamura","year":"2019","journal-title":"Clin Immunol"},{"key":"2023100619312121000_ljac016-B76","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2014.01.867","article-title":"Increased serum levels of interleukin 33 in patients with atopic dermatitis","volume":"70","author":"Tamagawa-Mineoka","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B77","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"2023100619312121000_ljac016-B78","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.20041503","article-title":"Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin","volume":"202","author":"Yoo","year":"2005","journal-title":"J Exp Med"},{"key":"2023100619312121000_ljac016-B79","author":"FierceBiotech"},{"key":"2023100619312121000_ljac016-B80","author":"AnaptysBio"},{"key":"2023100619312121000_ljac016-B81","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2023100619312121000_ljac016-B82","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase IIa clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B83","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.1801473","article-title":"The neuroimmune axis in skin sensation, inflammation, and immunity","volume":"202","author":"Trier","year":"2019","journal-title":"J Immunol"},{"key":"2023100619312121000_ljac016-B84","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"2023100619312121000_ljac016-B85","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed interleukin-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B86","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med"},{"key":"2023100619312121000_ljac016-B87","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B88","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B90","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B91","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B92","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B93","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B94","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.17218","article-title":"Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI \u2265 16) analysis of randomized phase 2B study","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619312121000_ljac016-B95","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"2023100619312121000_ljac016-B96","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","article-title":"Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb","volume":"150","author":"Miron","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"2023100619312121000_ljac016-B98","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023100619312121000_ljac016-B99","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2021.09.014","article-title":"IL-33 signaling in sensory neurons promotes dry skin itch","volume":"149","author":"Trier","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B100","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjd.18025","article-title":"Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus","volume":"181","author":"St\u00e4nder","year":"2019","journal-title":"Br J\u00a0Dermatol"},{"key":"2023100619312121000_ljac016-B101","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5114\/pdia.2013.38357","article-title":"Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus","volume":"30","author":"Teresiak-Miko\u0142ajczak","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"2023100619312121000_ljac016-B102","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2023100619312121000_ljac016-B103","author":"GlobeNewswire"},{"key":"2023100619312121000_ljac016-B104","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.17090","article-title":"Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial","volume":"35","author":"Welsh","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619312121000_ljac016-B105","doi-asserted-by":"crossref","first-page":"e89362","DOI":"10.1172\/jci.insight.89362","article-title":"Dual action of neurokinin-1 antagonists on Mas-related GPCRs","volume":"1","author":"Azimi","year":"2016","journal-title":"JCI Insight"},{"key":"2023100619312121000_ljac016-B106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","article-title":"Substance P activates Mas-related G protein-coupled receptors to induce itch","volume":"140","author":"Azimi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2023100619312121000_ljac016-B107","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed Mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"2023100619312121000_ljac016-B108","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis","volume":"127","author":"Tominaga","year":"2007","journal-title":"J Invest Dermatol"},{"key":"2023100619312121000_ljac016-B109","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuron.2014.02.046","article-title":"Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord","volume":"82","author":"Kardon","year":"2014","journal-title":"Neuron"},{"key":"2023100619312121000_ljac016-B110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jdermsci.2016.09.008","article-title":"Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD","volume":"84","author":"Elliott","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2023100619312121000_ljac016-B111","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2023100619312121000_ljac016-B112","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch\u2013scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"2023100619312121000_ljac016-B113","author":"Cara Therapeutics"},{"key":"2023100619312121000_ljac016-B114","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"2023100619312121000_ljac016-B117","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-021-00604-9","article-title":"Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes","volume":"22","author":"Silverberg","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023100619312121000_ljac016-B118","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"2023100619312121000_ljac016-B119","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2023100619312121000_ljac016-B120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","article-title":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis","volume":"6","author":"Katoh","year":"2022","journal-title":"JAAD Int"},{"key":"2023100619312121000_ljac016-B121","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B122","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2023100619312121000_ljac016-B123","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100619312121000_ljac016-B124","author":"US Food and Drug Administration"},{"key":"2023100619312121000_ljac016-B125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100619312121000_ljac016-B126","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100619312121000_ljac016-B127","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023100619312121000_ljac016-B128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/09546634.2020.1839008","article-title":"Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-\u200breported outcomes from two randomized monotherapy phase III trials","volume":"33","author":"Reich","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2023100619312121000_ljac016-B129","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.17278","article-title":"Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial","volume":"35","author":"Wollenberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619312121000_ljac016-B130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s13555-021-00577-x","article-title":"Baricitinib rapidly improves skin pain resulting in improved quality of life for patients with atopic dermatitis: analyses from BREEZE-AD1, 2, and 7","volume":"11","author":"Thyssen","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100619312121000_ljac016-B131","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","article-title":"Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase 3 studies","volume":"11","author":"Buhl","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100619312121000_ljac016-B132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2\u2005mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023100619312121000_ljac016-B133","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619312121000_ljac016-B134","author":"European Medicines Agency"},{"key":"2023100619312121000_ljac016-B135","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events\u00a0associated with JAK inhibitors in 126,815 reports from\u00a0the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"2023100619312121000_ljac016-B136","first-page":"877","article-title":"Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial","volume":"2021","author":"Zhao","journal-title":"Am J Clin Dermatol"},{"key":"2023100619312121000_ljac016-B137","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac016\/48517918\/ljac016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/6\/698\/51918891\/ljac016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/6\/698\/51918891\/ljac016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T06:02:35Z","timestamp":1701669755000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/6\/698\/6832303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":137,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,18]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac016","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2022,11,18]]}}}